Analysts forecast that Steris PLC (NYSE:STE) will report sales of $673.53 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Steris’ earnings. The lowest sales estimate is $669.10 million and the highest is $676.10 million. Steris reported sales of $638.76 million in the same quarter last year, which indicates a positive year over year growth rate of 5.4%. The company is expected to issue its next quarterly earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Steris will report full-year sales of $2.94 billion for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will post sales of $3.10 billion, with estimates ranging from $3.09 billion to $3.11 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Steris.

Steris (NYSE:STE) last posted its earnings results on Monday, May 13th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.44 by $0.09. Steris had a net margin of 10.93% and a return on equity of 13.34%. The firm had revenue of $768.00 million during the quarter, compared to analyst estimates of $738.87 million. During the same quarter in the prior year, the business posted $1.24 EPS. The business’s revenue was up 7.3% compared to the same quarter last year.

A number of brokerages recently weighed in on STE. Stephens reissued a “hold” rating and issued a $17.00 price target on shares of Capstar Financial in a report on Wednesday, May 15th. JMP Securities boosted their price target on shares of Steris from $135.00 to $150.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 22nd. Zacks Investment Research downgraded shares of German American Bancorp. from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Finally, KeyCorp boosted their price target on shares of Steris from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Wednesday, May 15th. Five equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $148.20.

In other Steris news, Director Jacqueline B. Kosecoff sold 3,609 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $132.22, for a total transaction of $477,181.98. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 119,000 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $132.56, for a total transaction of $15,774,640.00. The disclosure for this sale can be found here. Insiders sold a total of 244,145 shares of company stock worth $33,121,338 over the last three months. 2.36% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. lifted its holdings in shares of Steris by 20.6% in the fourth quarter. Advisors Asset Management Inc. now owns 19,934 shares of the medical equipment provider’s stock worth $2,130,000 after buying an additional 3,400 shares in the last quarter. Comerica Securities Inc. lifted its holdings in shares of Steris by 22.4% in the fourth quarter. Comerica Securities Inc. now owns 4,271 shares of the medical equipment provider’s stock worth $456,000 after buying an additional 782 shares in the last quarter. LPL Financial LLC lifted its holdings in shares of Steris by 7.1% in the fourth quarter. LPL Financial LLC now owns 9,589 shares of the medical equipment provider’s stock worth $1,025,000 after buying an additional 637 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Steris by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 27,470 shares of the medical equipment provider’s stock worth $2,936,000 after buying an additional 1,845 shares in the last quarter. Finally, AlphaCrest Capital Management LLC purchased a new stake in shares of Steris in the fourth quarter worth about $214,000. 83.38% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:STE traded down $2.24 during midday trading on Friday, reaching $147.98. The company had a trading volume of 711,228 shares, compared to its average volume of 483,942. The stock has a 50 day simple moving average of $142.73. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.82 and a current ratio of 2.27. The stock has a market capitalization of $12.66 billion, a PE ratio of 30.26 and a beta of 1.00. Steris has a 52-week low of $99.14 and a 52-week high of $154.09.

The business also recently declared a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Wednesday, June 12th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend was Tuesday, June 11th. Steris’s dividend payout ratio (DPR) is currently 27.81%.

About Steris

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

Further Reading: Determine Your Level of Risk Tolerance

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.